Cat. No. | Product name | CAS No. |
DCC3449 |
Momelotinib Dihydrochloride
Featured
Momelotinib (dihydrochloride) is a JAK1/JAK2 inhibitor that also antagonizes ACVR1, leading to downregulation of Hepcidin expression and increased availability of iron for erythropoiesis. Momelotinib (dihydrochloride) can reduce transfusion burden and spleen enlargement caused by myelofibrosis, showing potential value in research and application within the field of myelofibrosis. |
1380317-28-1 |
DCC3450 |
Momordicoside L
Natural antioxidant and antidiabetic agent |
81348-83-6 |
DCC3451 |
Mon-dnj
Novel iminosugar, downregulatiing the interferon γ receptor by dengue virus |
615253-61-7 |
DCC3452 |
Moracin T
Natural potent antioxidant agent |
1146113-27-0 |
DCC3453 |
Morellic Acid
Natural analogue of (-)-gambogic acid acting as a potent inhibitor of global predominant MRSA USA300 |
5304-71-2 |
DCC3454 |
Mosapramine Dihydrochloride
Potent dopamine antagonist with high affinity to the D2, D3, and D4 receptors, and with moderate affinity for the 5-HT2 receptors |
98043-60-8 |
DCC3455 |
Naucledine
Natural antibacterial, antileishmanial, and antifungal agent |
26238-84-6 |
DCC3456 |
Mp-10 Succinate
Potent and Specific PDE10A inhibitor |
1037309-45-7 |
DCC3457 |
Mp1104
Novel mixed kappa-delta opioid receptor agonist with anti-cocaine properties and reduced side-effects in rats |
|
DCC3458 |
Mpges-1 Inhibitor-2
Novel potent and selective microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor |
|
DCC3459 |
mpi621
Novel anti-cancer agent, being more potent and safer than conventional indomethacin |
1428774-23-5 |
DCC3460 |
Mpk576
Novel selective class IIb histone deacetylase inhibitor (HDACi), dose-dependently decreasing the viability of Acanthamoeba trophozoites |
|
DCC3461 |
Mpo-0029
Potent and selective COX-2 inhibitor |
248281-84-8 |
DCC3462 |
Mpp Dihydrochloride
Specific estrogen receptor α (ERα) antagonist |
911295-24-4 |
DCC3463 |
Mpro-in-n3
Novel main protease (Mpro) inhibitor, inhibiting MHV-A29, HCoV-229E, FOPV replication, and SARS-CoV-2 viral cell entry |
884650-98-0 |
DCC3464 |
mps1 Inhibitor I
Novel Mps1 Kinase Inhibitor |
1226900-59-9 |
DCC3465 |
Mps-bay2b
Novel inhibitor of MPS1 |
1263420-68-3 |
DCC3466 |
Mpt0b206
Novel tubulin polymerization inhibitor |
|
DCC3467 |
Mpt0b451
Novel Dual HDAC6 and Tubulin Inhibitor, Displaying Anti-tumor Ability in Human Cancer Cells |
|
DCC3468 |
Mptp-in-22
Novel mitochondrial permeability transition pore (mPTP) inhibitor |
1223569-03-6 |
DCC3469 |
Mpx-007
Novel potent and selective antagonist of GluN2A-containing NMDA receptors |
1688685-29-1 |
DCC3470 |
Mq02-439
Novel highly potent and selective 5-HT2C agonist |
|
DCC3471 |
Mr22388
Novel, potent inducer of apoptosis via the MAP kinase pathways. Inhibitor of several kinases including the tyrosine kinase FLT3-ITD |
258270-07-4 |
DCC3472 |
Mr6-31-2
Novel inhibitor of the main protease (Mpro) of SARS-CoV-2 |
|
DCC3473 |
Mrgprx1 Pam 1t
Novel positive allosteric modulator (PAM) of mas-related G protein-coupled receptor X1 (MRGPRX1), reducing behavioral heat hypersensitivity in humanized MRGPRX1 mice, demonstrating the therapeutic potential in treating neuropathic pain |
|
DCC3474 |
Mrgx1-activator-1
Activator of MrgX1 receptor signaling |
793731-95-0 |
DCC3475 |
Mri-1891
Novel peripheral CB1R antagonist, being highly biased toward inhibiting CB1R-induced β-arrestin-2 (βArr2) recruitment over G-protein activation |
|
DCC3476 |
Mrl-248
Novel potent and selective RORγT inhibitor, showing no appreciable activity against a panel of related nuclear hormone receptors |
|
DCC3477 |
Mrl-299
Novel potent RORγT inhibitor |
|
DCC3478 |
Mrl-367
Novel potent and selective RORγT inhibitor, showing no appreciable activity against a panel of related nuclear hormone receptors |
|
DCC3479 |
Mrl-770
Novel selective and reproducible inhibitor of DNA synthesis in E. coli JL553 |
|
DCC3480 |
Mrs2220
Selective enhancer of the ATP effects at fast desensitizing P2X (P2X1 and P2X3) receptors |
1027168-08-6 |
DCC3481 |
mrs2690
Potent P2Y14 receptor agonist |
15039-58-4 |
DCC3482 |
mrs2693 Trisodium
Selective P2Y6 agonist |
911391-37-2 |
DCC3483 |
mrs2768
Selective P2Y2 agonist |
1047980-83-5 |
DCC3484 |
mrs2957
Potent P2Y6 agonist |
1228271-30-4 |
DCC3485 |
Mrs2964
Potent and selective P2Y6 receptor agonist |
|
DCC3486 |
Mrs4598
Novel highly potent human CD73 inhibitor (K i = 0.673 nM) |
|
DCC3487 |
Mrs4608
Novel potent antagonist of P2Y 14 receptor (P2Y 14 R) (IC 50 ~20 nM at hP2Y 14 R/mP2Y 14 R) |
|
DCC3488 |
Mrs4654
Novel potent P2Y14 Receptor Antagonist (IC 50 , 15 nM) |
|
DCC3489 |
Mrs7396
Bitopic fluorescent antagonist of the A2A adenosine receptor |
|
DCC3490 |
Mrs7469
Novel highly selective A1 adenosine receptor (A1AR) agonist |
|
DCC3491 |
Mrs7591
Novel Partial Agonist of Human and Mouse A3 Adenosine Receptors (Ki = 10.9/17.8 nM, at human/mouse A3AR) |
|
DCC3492 |
Mrs7799
Novel highly potent A3 adenosine receptor (A3AR) antagonist with Kd values (nM): 0.55 (human), 3.74 (mouse), and 2.80 (rat) |
|
DCC3493 |
Mrt-68601 Hydrochloride
Potent inhibitor of TANK-binding kinase-1 (TBK1)/IKKepislon kinases |
1962928-25-1 |
DCC3494 |
Mrt-92 Hydrochloride
Novel inhibitor of Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor |
1428307-52-1 |
DCC3495 |
Mrz-8676
Novel, selective, orally bioavailable, negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5) |
872122-36-6 |
DCC3496 |
ms0017509
Inhibitor of DNA damage repair |
21945-37-9 |
DCC3497 |
ms0019266
Novel inhibitor of DNA damage repair |
124285-22-9 |
DCC3498 |
Ms2126
Novel inhibitor of Human p53 and CREB Binding Protein (CREBBP) interaction |
16078-42-5 |
DCC3499 |
Ms2177
Novel potent and selective SETD8 inhibitor |
|
DCC3500 |
Ms2i6a
Mitochondrial tRNA-specific modification, regulating efficient mitochondrial translation and energy metabolism in mammals |
20859-00-1 |
DCC3501 |
Msc2524070
Novel potent tankyrase (TNKS) inhibitor (EC 50 : 2 nM) |
|
DCC3502 |
Msc-4381
Novel inhibitor of SLC16A3 |
|
DCC3503 |
Msd-496486311
Novel potent and selective PI3Kδ inhibitor |
|
DCC3504 |
Msk-195
Potent TRPV1 agonist |
289902-82-5 |
DCC3505 |
Mßl-in-2i
Novel potent broad-spectrum metallo-β-lactamase (MβL) inhibitor, inhibiting the MβLs NDM-1, VIM-2, ImiS, and L1 |
305376-89-0 |
DCC3506 |
Mt1/2 Agonist (s)-3b
Novel BBB permeable potent MT1 and MT2 ligand (MT1, Ki = 0.031 nM; MT2, Ki = 0.070 nM) with good metabolic stability in human hepatic microsomes |
|
DCC3507 |
Mtc420
Novel antituberculosis agent. targeting the respiratory chain of Mycobacterium tuberculosis (Mtb) and being effective against multi drug resistant (MDR) Mtb |
2088930-66-7 |
DCC3508 |
Mtd12813
Novel minimized theta-defensin, being highly effective against CRE pathogens K. pneumoniae and E. coli in vivo, significantly enhancing survival by promoting rapid host-mediated bacterial clearance and by modulating pathologic cytokine responses, restorin |
|
DCC3509 |
Mtdl-4e
Novel resveratrol-based multitarget-directed ligand, cellularly activating the NRF2-ARE pathway (CD = 9.83 μM), selectively inhibiting both hMAO-B and QR2 (IC 50 s = 8.05 and 0.57 μM), and promoting hippocampal neurogenesis |
|
DCC3510 |
Mthp Hydrobromide
Selective antagonist of melanocortin-4 receptor (MC4R) |
325959-81-7 |
DCC3511 |
Mtmox32e
Novel Mithramycin A (MTM) 2'-oxime (MTMox) conjugate, displaying an 11-fold increase in plasma exposure and improved efficacy in an Ewing sarcoma xenograft |
|
DCC3512 |
Mtor Inhibitor-7
Novel, potent, and selective brain-penetrant ATP-competitive mTOR inhibitor |
|
DCC3513 |
Mtor/hdac1-in-12l
Novel potent dual inhibitor of mTOR and HDAC1 |
|
DCC3514 |
Mtorc1-in-1
Novel selective inhibitor of mTORC1, yielding potent inhibition of glucose uptake |
|
DCC3515 |
Mtorc1-in-i
Novel selective mTORC1 inhibitor, directly targeting class I glucose transporters |
|
DCC3516 |
Mtor-in-17
Novel mTOR inhibitor, exhibiting potent anticancer activities against four tumor cell lines, including MCF-7, HeLa, MGC-803, and C6, inducing cell death via apoptosis by targeting both mTORC1 and mTORC2 within cells and arrests the cell cycle of HeLa at t |
|
DCC3517 |
Mtpdds
Novel mitochondria-targeted photoactivatable real-time probe, being phototriggered by either UV (one-photon) or NIR (two-photon) light to form a fluorescent coumarin product and facilitate the release of drug payload |
|
DCC3518 |
Mtsea Hydrobromide
Useful probe in the mapping of membrane proteins, such as ion channels and transports proteins, as well as enzymes and receptors. |
16599-33-0 |
DCC3519 |
Mtsea Hydrochloride
Useful probe in the mapping of membrane proteins, such as ion channels and transports proteins, as well as enzymes and receptors. |
37597-96-9 |
DCC3520 |
Multitarget Ligand B6
Novel potent multitarget ligand |
220459-72-3 |
DCC3521 |
Mura-in-1 (zinc6129841)
Novel potent MurA inhibitor |
577789-80-1 |
DCC3522 |
Murizatoclax
Novel potent and selective MCL-1 inhibitor |
2245848-05-7 |
DCC3523 |
Mutant Idh1 Inhibitor
Novel potent mutant IDH1 R132H inhibitor |
1429180-08-4 |
DCC3524 |
Mv061194
Novel potent and selective cathepsin K (Cat K) inhibitor |
1021423-50-6 |
DCC3525 |
Mw01-2-151srm
CNS-penetrant, selective restorer of injury- or disease-induced overproduction of proinflammatory cytokines towards homeostasis. Selective suppressor of beta amyloid (Aβ)-induced glia proinflammatory cytokine production |
886208-65-7 |
DCC3526 |
mw1219
Novel GPR119 agonist with Anti-Diabetic Efficacy in db/db Mice |
54087-06-8 |
DCC3527 |
Mwp00839
Novel mitophagy activator |
|
DCC3528 |
mycothiol
Major thiol in most actinomycetes involved in mycothiol biosynthesis and mycothiol-dependent enzymes such as mycothiol-dependent formaldehyde dehydrogenase and mycothione reductase |
192126-76-4 |
DCC3529 |
Mycro1
Novel inhibitor of the protein-protein interactions between the bHLHZip proteins c-Myc and Max |
313987-85-8 |
DCC3530 |
Mycro2
Novel inhibitor of the protein-protein interactions between the bHLHZip proteins c-Myc and Max |
314049-21-3 |
DCC3531 |
My-d-4
Novel inhibitor of zinc finger DHHC domain-containing (zDHHC) enzymes |
|
DCC3532 |
Myotoxin Ii (105-117)
Myotoxin II fragment |
223596-96-1 |
DCC3533 |
myovin-1
Novel potent, reversible and uncompetitive inhibitor of actin-stimulated ATPase activity of myosin V |
1259177-59-7 |
DCC3534 |
Myra-a
Novel inducer of apoptosis in a Myc-dependent manner, inhibiting Myc-driven transformation and disrupting MYC-Max interaction |
3900-43-4 |
DCC3535 |
Myrtucommulone
Inhibitor of the chaperonin activity of HSP60, correlating to LONP and LRP130 aggregation |
54247-21-1 |
DCC3536 |
Myxopyronin A
Bacterial RNA polymerase (RNAP) inhibitor |
88192-98-7 |
DCC3537 |
Mzp-54
Novel potent and selective PROTAC degrader of BRD3/4 |
2010159-47-2 |
DCC3538 |
N,n-dimethylsphingosine
Competitive inhibitor of both SPHK1 and SPHK2 |
119567-63-4 |
DCC3539 |
n00236460
Glucokinase activator (GKA) |
1466419-40-8 |
DCC3540 |
N6-allyladenosine
Novel RNA labeling probe through both metabolic and enzyme-assisted manners |
15763-12-9 |
DCC3541 |
N6-methyl-d3-adenosine
Deuterium labeled m6A used in important m6A physiological pathways related studies |
139896-43-8 |
DCC3542 |
Na-aaf
Alkylating agent, forming DNA adducts at the C-8 position in guanine, resulting in single strand breaks, demonstrating carcinogenic action |
6098-44-8 |
DCC3543 |
Nabiximols
Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) combination for the treatment of multiple sclerosis (MS)-related moderate to severe spasticity |
56575-23-6 |
DCC3544 |
N-acetylloline
Derivative of loline |
4914-36-7 |
DCC3545 |
N-adamantanylglycinamide Hbr
Novel antiviral agent against the replication of influenza virus A/H3N2 subtype in Madin-Darby canine kidney (MDCK) cells |
54993-13-4 |
DCC3546 |
Nadide
Coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage |
53-84-9 |
DCC3547 |
Nadph Tetrasodium Salt
Electron donor and cofactor for many redox enzymes including nitric oxide synthetase |
2646-71-1 |
DCC3548 |
Nafoxidine
Partial estrogen antagonist, inhibiting angiogenesis in some tissues by blocking the effects of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), inducing oxidative stress, protein kinase C and calcium signaling |
1845-11-0 |
DCC3549 |
Nag-26
Novel potent full agonist for orexin receptor |
|
DCC3550 |
Nai003
Novel highly selective antibacterial agent against Propionibacterium acnes |
1888304-21-9 |
DCC3551 |
Nalbuphine Hydrochloride
Mixed agonist/antagonist opioid modulator, binding with high affinity to the MOR and KOR, and having relatively low affinity for the DOR |
23277-43-2 |
DCC3552 |
Naph-o2
Novel fluorescent probe for detection of endogenously produced Naph-O2˙– in living cells and tissues |
|
DCC3553 |
Naphthyridine-azaquinolone
Novel repeat-structure-specific DNA ligand, specifically binding slipped-CAG DNA intermediates of expansion mutations |
|
DCC3554 |
Naphyrone Hydrochloride
Triple reuptake inhibitor |
850352-11-3 |
DCC3555 |
Napi2b Inhibitor 15
Novel Gut-Restricted Inhibitor of Intestinal Sodium-Dependent Phosphate Transport Protein 2b (NaPi2b) for the Treatment of Hyperphosphatemia |
|
DCC3556 |
Napitane Mesylate
Antagonist of alpha-2 adrenergic receptors and inhibitor of the neuronal uptake of norepinephrine |
149189-73-1 |
DCC3557 |
Napsagatran
Inhibitor of extrinsic and intrinsic thrombin generation, inhibiting clot-bound and free (fluid-phase thrombin) |
159668-20-9 |
DCC3558 |
N-arachidonoyl Taurine
Activator of the transient receptor potential vanilloid (TRPV) channels TRPV1 and TRPV4 |
119959-65-8 |
DCC3559 |
Nargenicin
Natural DnaE1 blocker, inducing a DNA damage response in Mycobacterium tuberculosis (Mtb) and inhibiting growth by blocking the replicative DNA polymerase, DnaE1 |
70695-02-2 |
DCC3560 |
Tylophorine
Potent suppressor of inducible nitric oxide synthase (iNOS; NOS II) |
482-20-2 |
DCC3561 |
Nav1.1-in-b
Novel selective NaV1.1 inhibitor, reducing visceral hypersensitivity |
924862-21-5 |
DCC3562 |
Nav1.7 Blocker-13
Novel selective blocker of NaV1.7 with little affinity for NaV 1.2, 1.3, or 1.6, being more potent at human vs guinea pig NaV1.7 |
|
DCC3563 |
Nav1.7 Blocker-24
Potent and selective blocker of voltage-gated Nav1.7 sodium channels |
1315451-25-2 |
DCC3564 |
Nav1.7 Blocker-801
Potent NaV1.7 blocker, being 5-10 fold more potent than NaV 1.2 and NaV 1.6 |
1235403-75-4 |
DCC3565 |
Navarixin
Novel CXC chemokine receptor 2 (CXCR2) antagonist |
862464-58-2 |
DCC3566 |
Naveglitazar
Dual peroxisome proliferator-activated receptor gamma and alpha (PPARgamma and PPARalpha) agonist |
476436-68-7 |
DCC3567 |
Naxifylline
Potent and selective A1 adenosine receptor antagonist |
166374-49-8 |
DCC3568 |
Nb-360
Biological Active Reagents |
1262857-73-7 |
DCC3569 |
Nb-caged Tyrosine Hydrochloride
L-Tyrosine caged with photosensitive ortho-nitrobenzyl side chain |
207727-86-4 |
DCC3570 |
Nbd-09027
Novel HIV-1 entry inhibitor |
1376434-43-3 |
DCC3571 |
Nbd-10007
Novel HIV-1 entry inhibitor |
1375736-65-4 |
DCC3572 |
Nbd-14136
Novel CD4-mimetic HIV-1 entry inhibitor |
|
DCC3573 |
N-bn-thaz Fumarate
Potent agonist of the human 5-HT2A and 5-HT2C receptors |
125115-67-5 |
DCC3574 |
Nboh-2c-cn Hydrochloride
Potent and selective 5-HT2A receptor agonist |
1539266-32-4 |
DCC3575 |
Nbti-5463
Novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy |
|
DCC3576 |
nc00094221
M. tuberculosis Dihydrofolate Reductase Inhibitor |
139337-61-4 |
DCC3577 |
Nc2213
Novel inhibitor of methionine aminopeptidase 2 (MetAP2) |
|
DCC3578 |
Ncats-sm1440
First-in-class, potent, and selective Lactate dehydrogenase inhibitor |
|
DCC3579 |
Ncats-sm1441
First-in-class, potent, and selective Lactate dehydrogenase inhibitor |
|
DCC3580 |
Ncb0970
Less active trans-isomer of NCB-0846, acting as the negative control for NCB-0846, showing 13-fold weaker TNIK enzyme-inhibitory activity |
|
DCC3581 |
Ncdm-32
Potent pan KDM Inhibitor, inhibiting KDM2A, KDM7A, KDM7B, KDM4A, KDM4C, and KDM5A |
|
DCC3582 |
Ncgc00117362
Novel inhibitor of ovarian cancer metastasis, adhesion, invasion and proliferation |
|
DCC3583 |
Ncgc00120943
Novel Agonist for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions |
902842-20-0 |
DCC3584 |
ncgc00161856
The first small-molecule inverse agonist for the thyroid-stimulating hormone receptor (TSHR) |
361187-13-5 |
DCC3585 |
ncgc00242595
TSHR neutral antagonist, inhibiting stimulated signaling but not basal signaling |
1338824-23-9 |
DCC3586 |
Ncgc00249987
Novel allosteric Eya2 phosphatase inhibitor, specifically targeting migration, invadopodia formation, and invasion of lung cancer cells |
|
DCC3587 |
Ncgc00262654
Novel AMA1-RON2 Inhibitor |
|
DCC3588 |
Ncgc2327
Novel potent inhibitor of IRAK1/4 and FLT3 |
|
DCC3589 |
Nco-04
Novel SIRT1 inhibitor, inducing cell death in adult T-cell leukaemia cells |
|
DCC3590 |
Ncrw0005-f05
Novel GPR139 receptor agonist |
342779-66-2 |
DCC3591 |
Ncs-382
Analogue of γ-hydroxybutyric acid (GHB), acting as a substrate for both the monocarboxylate transporter subtype 1 (MCT1) and subtype 4 (MCT4) |
131733-92-1 |
DCC3592 |
Ncs-8591
Beclin 1 mimetic, selectively binding to Bcl-xL and inducing autophagy, showing potent cytotoxicity in PC-3, PC-3a and DU145 prostate cancer cells |
6286-97-1 |
DCC3593 |
Nctu-alan-2026
Novel blocker of the interaction between FGF1 and FGFRD2 to inhibit cell proliferation, showing potent antiproliferent with less cytotoxicity. |
|
DCC3594 |
ncx-2057
Novel NO-donor, suppressing inflammatory and nociceptive responses |
475561-36-5 |
DCC3595 |
Ncx-6560
Novel HMG-CoA reductase inhibitor and nitric oxide donor |
803728-45-2 |
DCC3596 |
N-cyano-sch-12679 Bromide
Cyanogen Bromide adduct of (R)-SCH-12679, a D1 antagonist |
|
DCC3597 |
Levomepromazine Maleate
Tricyclic antidepressant (TCA), acting as a serotonin–norepinephrine reuptake inhibitor (SNRI) and also having other activities including antihistamine, antiadrenergic, antiserotonergic, anticholinergic, and sodium channel-blocking effects |
7104-38-3 |
DCC3598 |
Nd1-yl2
Novel degrader of steroid receptor co-activator 1 (SRC-1) |
|
DCC3599 |
Nd-2110
Novel potent and highly specific IRAK4 inhibitor |
1388894-17-4 |
DCC3600 |
Nd-322 Hydrochloride
Selective water-soluble gelatinase inhibitor |
1333379-23-9 |
DCC3601 |
Nd-364
Potent and selective inhibitor for gelatinases, matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MPP9) |
869577-61-7 |
DCC3602 |
nd7001
Inhibitor of Phosphodiesterase (PDE)-2 |
855170-53-5 |
DCC3603 |
N-demethyldiltiazem
Precursor for radiolabeled diltiazem |
92700-53-3 |
DCC3604 |
N-desmethyl Loperamide
Major metabolite of loperamide, also used as the precusor for radiolabelled loperamide |
66164-07-6 |
DCC3605 |
Ndi-10
Novel G4-DNA ligand, promoting transcription in Gram-positive bacteria and repressing transcription in Gram-negatives |
|
DCC3606 |
Ndm-1 Inhibitor-2
Novel Inhibitor of New Delhi Metallo-β-lactamase-1 (NDM-1) |
665013-76-3 |
DCC3607 |
nec-1i
Negative control compound for Necrostatin-1 related assays |
64419-92-7 |
DCC3608 |
necrostatin-21
Novel necroptosis inhibitor |
169136-33-8 |
DCC3609 |
necrox-18
Novel inhibitor of caspase-independent cell death with necrotic morphol, distinctly different from apoptosis, autophagy, and necroptosis, displaying strong mitochondrial reactive oxygen species and ONOO- scavenging activity |
1174671-89-6 |
DCC3610 |
Nefopam
Non-narcotic analgesic for the relief of acute and chronic pain |
13669-70-0 |
DCC3611 |
Neil1-in-p2
Novel Inhibitor of DNA Glycosylases, inhibiting NEIL1 activity |
|
DCC3612 |
Nek2/7-in-51
Novel ATP-competitive inhibitor of Nek2 and Nek7 |
|
DCC3613 |
Neobractatin
Natural inhibitor of tumor metastasis by upregulating the RNA-binding-protein MBNL2, inducing cell cycle arrest through multiple signaling pathways including RNA binding protein CELF6 |
|
DCC3614 |
neocryptolepine
Inhibitor of the formation of |
114414-78-7 |
DCC3615 |
Neothalfine
Potent natural anti-tumor agent against metastatic colorectal cancer, resulting in cell cycle arrest at the G2/M phase and inducing apoptosis through the dysfunction of mitochondria to trigger intrinsic apoptotic pathway by untargeted metabolomic method, |
|
DCC3616 |
Nepetin [520-11-6]
Natural inducer of autophagy and apoptosis, inhibiting glutamate overexcitation and upregulation of the Wnt/β-catenin signaling pathway |
520-11-6 |
DCC3617 |
Neq0502
Novel AR inhibitor, being selective for the testosterone stimulated AR-dependent prostate cancer cell |
|
DCC3618 |
neq135
The first potent NAD-driven small molecular inhibitor of TcGAPDH (Trypanosoma cruzi glyceraldehyde 3-phosphate dehydrogenase) |
224175-74-0 |
DCC3619 |
nequimed176
Novel non-peptidic, non-covalent cruzain inhibitor |
1030685-11-0 |
DCC3620 |
Nesiritide Acetate
Human B-type natriuretic peptide, facilitating cardiovascular fluid homeostasis through counterregulation of the renin-angiotensin-aldosterone system, stimulating cyclic guanosine monophosphate, leading to smooth muscle cell relaxation |
114471-18-0 |
DCC3621 |
Nestifylline
Anti-inflammatory, antibronchospastic agent |
116763-36-1 |
DCC3622 |
Netarsudil Mesylate
Novel dual Rho Kinase and norepinephrine transporter (ROCK/NET) inhibitor |
1422144-42-0 |
DCC3623 |
Net-c343
Novel fluorescent RXR antagonist |
|
DCC3624 |
N-ethylglycine
Lidocaine metabolite, showing antinociceptive effects, inhibiting GlyT1-mediated glycine uptake |
627-01-0 |
DCC3625 |
N-ethylmaleimide
Modulator of the T1007 site, resulting in rapid activation of this transporter and potentiating KCC2 activity |
128-53-0 |
DCC3626 |
Neu321
Ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth |
1426937-35-0 |
DCC3627 |
Neu-4854
Novel potent Trypanosoma brucei Inhibitor |
|
DCC3628 |
Neu617
Novel inhibitor of the growth of protozoan parasites, against T. brucei bloodstream proliferation |
1432450-82-2 |
DCC3629 |
Neu-730
Novel inhibitor of TbrPDEB1, showing modest inhibition of T. brucei proliferation |
1622300-88-2 |
DCC3630 |
Neurodazole
Novel neurogenic inducer for converting pluripotent P19 cells into electrophysiologically active neurons |
|
DCC3631 |
Neuroprotectant-7
Novel neuroprotectant for Alzheimers disease, showing significant neuroprotection and antioxidative properties, crossing the blood-brain barrier (BBB) |
1610504-84-1 |
DCC3632 |
Neurotensin(8-13)
The neurotensin active fragment, eliciting behavioral responses typical of clinically used antipsychotic drugs when administered directly to the brain |
60482-95-3 |
DCC3633 |
Nexturastat A-crbn-12d
Novel potent HDAC6 degrader with promising antiproliferation activity in multiple myeloma (MM) cells |
|
DCC3634 |
Nfat-133
Inhibitor of NFAT-mediated transcription, leading to the suppression of interleukin-2 expression and T cell proliferation, showing immunosuppressive, antidiabetic, and antitrypanosomal activities |
|
DCC3635 |
Nf-kappab Inhibitor-2
First-in-class inhibitor of NF-κB signaling pathway by preventing the maturation of a rate-limiting multiprotein complex necessary for IKK activation |
|
DCC3636 |
N-formyl-met-phe
Neutrophil Dysfunction Test Peptide |
22008-60-2 |
DCC3637 |
Nfu1827
Novel inhibitor of human cytomegalovirus (HCMV) infection |
|
DCC3638 |
Ngd 98-2
New generation, topology 2 selective orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist |
355836-54-3 |
DCC3639 |
Ngd-8243
Novel TRPV1 Antagonist |
573678-04-3 |
DCC3640 |
Ngd9002
New generation, topology 2 selective corticotropin releasing factor-1 (CRF-1) receptor antagonist |
666256-06-0 |
DCC3641 |
Ngp1-01
Brain-permeable dual blocker of neuronal voltage- and ligand-operated calcium channels, acting as chemosensitizer and circumvent the resistance of the plasmodia parasite against chloroquine (CQ) by inhibiting the p-glycoprotein efflux pump and enabling th |
33226-57-2 |
DCC3642 |
Nh2-bodipy
Novel cell-permeant probe for the super-resolution imaging of the endoplasmic reticulum in live cells |
|
DCC3643 |
Nh2-nplh2
Novel luciferin analog, enabling both sensitive and highly resolved imaging in vivo |
1629640-37-4 |
DCC3644 |
Nh2-uamc1110
UAMC1110 Conjugate Linker |
|
DCC3645 |
Nhi-1j
Selective Inhibitor of Human Lactate Dehydrogenase Isoform A (LDH-A) |
1269802-68-7 |
DCC3646 |
Nicodicosapent
Novel inhibitor of the sterol regulatory element binding protein (SREBP) |
1269181-69-2 |
DCC3647 |
Nicofibrate
Antilipidemic agent |
31980-29-7 |
DCC3648 |
Nifrofam
Novel fluorescent probe for imaging α4β2* nAChRs |